This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Larsen, A. K. Articles by Bigg, D. C. H. Search for Related Content PubMed PubMed Citation Articles by Larsen, A. K. Articles by Bigg, D. C. H.

Unusual Potency of BN 80915, a Novel Fluorinated E-ring Modified Camptothecin, toward Human Colon Carcinoma Cells

Centre National de la Recherche Scientifique UMR 8532, Institut Gustave-Roussy, F-94805 Villejuif, France [A. K. L., C. G., G. C., S. Y. P., I. N.]; Institut Henri Beaufour, F-91966 Les Ulis, France [O. L., L. L-G., D. C. H. B.]

BN 80915 is the lead compound from a novel class of E-ring modified camptothecin analogues, the homocamptothecins, which show potent antitumor activities in animal models. Here, we report that BN 80915 induces up to 2-fold more cleavable complexes between plasmid DNA and purified human topoisomerase I than SN-38 and camptothecin. BN 80915 also induces DNA-topoisomerase I complexes in living HT-29 colon carcinoma cells, as shown by the in vivo link assay. BN 80915 is an extremely potent inducer of DNA-protein complexes in these cells starting at a concentration of 5 nM in the media. BN 80915 is clearly more potent than SN-38, because at least 20 times more SN-38 is needed to induce comparable levels of cleavable complexes. Kinetic experiments show that BN 80915 induces cleavable complexes within minutes that remain stable for at least 6 h in the presence of drug. Whereas the majority of the complexes are reversed within 15 min after drug removal, a substantial fraction (30%) persists for at least 4 h, in contrast with SN-38-treated cells, where all complexes have disappeared by this time. BN 80915 shows strong antiproliferative effects toward HT-29 cells with an IC₅₀ of 0.3 nM compared with 20 nM for SN-38 and 40 nM for topotecan. BN 80915 is also potent against other colon carcinoma cells as well as toward cells growing in three dimensions as multicellular spheroids. HL-60 cells expressing functional P-glycoprotein or multidrug resistance protein show no cross-resistance toward BN 80915. Taken together, our results show that BN 80915 is unusually potent toward human colon carcinoma cells because of the formation of high levels of stable, covalent DNA-topoisomerase complexes.

This article has been cited by other articles:

				Z. Liao, R. W. Robey, J. Guirouilh-Barbat, K. K. W. To, O. Polgar, S. E. Bates, and Y. Pommier Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan Mol. Pharmacol., February 1, 2008; 73(2): 490 - 497. [Abstract] [Full Text] [PDF]

				D. J. Baker, G. Wuenschell, L. Xia, J. Termini, S. E. Bates, A. D. Riggs, and T. R. O'Connor Nucleotide Excision Repair Eliminates Unique DNA-Protein Cross-links from Mammalian Cells J. Biol. Chem., August 3, 2007; 282(31): 22592 - 22604. [Abstract] [Full Text] [PDF]

				L Scott, O Soepenberg, J Verweij, M. de Jonge, A. Th Planting, D McGovern, P Principe, R Obach, and C Twelves A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours Ann. Onc., March 1, 2007; 18(3): 569 - 575. [Abstract] [Full Text] [PDF]

				S. E. Bates, W. Y. Medina-Perez, G. Kohlhagen, S. Antony, T. Nadjem, R. W. Robey, and Y. Pommier ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 836 - 842. [Abstract] [Full Text] [PDF]

				H. Gelderblom, R. Salazar, J. Verweij, G. Pentheroudakis, M. J. A. de Jonge, M. Devlin, C. van Hooije, F. Seguy, R. Obach, J. Prunonosa, et al. Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors Clin. Cancer Res., September 15, 2003; 9(11): 4101 - 4107. [Abstract] [Full Text] [PDF]

				V. Poindessous, F. Koeppel, E. Raymond, M. Comisso, S. J. Waters, and A. K. Larsen Marked Activity of Irofulven toward Human Carcinoma Cells: Comparison with Cisplatin and Ecteinascidin Clin. Cancer Res., July 1, 2003; 9(7): 2817 - 2825. [Abstract] [Full Text] [PDF]

				A. Lansiaux, M. Facompre, N. Wattez, M.-P. Hildebrand, C. Bal, D. Demarquay, O. Lavergne, D. C. H. Bigg, and C. Bailly Apoptosis Induced by the Homocamptothecin Anticancer Drug BN80915 in HL-60 Cells Mol. Pharmacol., September 1, 2001; 60(3): 450 - 461. [Abstract] [Full Text] [PDF]